AI Article Synopsis
- This study investigates if a PSMA-PET scan from the skull base to proximal thigh is sufficient for detecting bone metastases in prostate cancer patients.
- A retrospective analysis of 1050 PET scans revealed significant correlations between PSA levels and the presence of bone metastases, identifying that most metastases occur in patients with higher numbers of total metastases.
- The study concludes that specific PSA cut-off values (11.15 ng/mL for below the thigh and 12.86 ng/mL for above the skull base) can effectively indicate the presence of bone metastases, showcasing the potential for optimized imaging strategies.
Article Abstract
Aim: Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) is a widely used diagnostic tool in patients with prostate cancer (PC). However, due to the limited availability of PET scanners and relevant acquisition costs, it is important to consider the indications and acquisition time. The aim of this investigation was to determine whether a PET scan from the skull base to the proximal thigh is sufficient to detect the presence of bone metastases.
Methods: A retrospective analysis was conducted on 1050 consecutive [F]PSMA-1007-PET-CT scans from the head to the proximal lower leg. The PET scans were categorised according to the presence and amount of bone metastases: (1) 1-5, (2) 6-19 and (3) ≥20. Additionally, the PET scans were evaluated for the presence of bone metastases below the proximal thigh as well as bone metastases above the skull base. Imaging results were compared to patients PSA values.
Results: Of the 391 patients with bone metastases, 146 (37.3%) exhibited metastases located below the proximal thigh and 104 (26.6%) above the skull base. The majority of bone metastases located below the proximal thigh (145, 99.3%) and above the skull base (94, 90.4%) were identified in patients with more than five bone metastases. No solitary distal metastasis was detected. The PSA value correlated significantly with number of bone metastases (e. g., 1-5 vs. ≥20 bone metastases, < 0.001) and was significantly higher in patients with distal bone metastases ( < 0.001). ROC analysis showed that a PSA value of 11.15 ng/mL is the optimal cut-off for detecting bone metastases located below the proximal thigh, with an AUC of 0.919 (95% CI: 0.892-0.945, sensitivity 87%, specificity 86%). Similarly, the PSA value of 12.86 ng/mL is the optimal cut-off for detecting bone metastases above the skull base with an AUC of 0.904 (95% CI: 0.874-0.935, sensitivity 87%, specificity 83%). CONCLUSION: PSMA-PET acquisition protocols from the skull base to the proximal femur may be sufficient to accurately detect bone metastatic disease in PC. PSA values can provide decision support for individual PET acquisition protocols.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1055/a-2344-6825 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Prognostic factors in patients with localized and metastatic alveolar rhabdomyosarcoma. A report from two studies and two registries of the Cooperative Weichteilsarkom Studiengruppe CWS.
Cancer Med
January 2025
Department for Children and Adolescents, University Hospital Frankfurt, Goethe University, Frankfurt am Main, Germany.
Background: The histologic classification of rhabdomyosarcoma (RMS) as alveolar (aRMS) or embryonal (eRMS) is of prognostic importance, with the aRMS being associated with a worse outcome. Specific gene fusions (PAX3/7::FOXO1) found in the majority of aRMS have been recognized as markers associated with poor prognosis and are included in current risk stratification instead of histologic subtypes in localized disease. In metastatic disease, the independent prognostic significance of fusion status has not been definitively established.
View Article and Find Full Text PDFUnusual outcome of treatment of thymoma with immunotherapy: case report.
Mediastinum
November 2024
Department of Oncology, Mayo Clinic, Rochester, MN, USA.
Background: Thymoma is a rare mediastinal neoplasm originating from thymic epithelial cells, often associated with paraneoplastic syndromes. These syndromes can manifest as a range of autoimmune disorders, including myasthenia gravis, pure red cell aplasia, and aplastic anemia. Clinical trials involving the use of immune checkpoint inhibitors (ICIs) in thymoma have been complicated by a high incidence of immune-related adverse effects (irAEs).
View Article and Find Full Text PDFTreatment of Distal Femoral Malignant Mesenchymal Tumor With Extensor Mechanism Transfer: A Case Report and Surgical Technique.
Cureus
December 2024
Orthopaedics and Traumatology, Cerrahpaşa Faculty of Medicine, Istanbul University-Cerrahpaşa, Istanbul, TUR.
Malignant mesenchymal tumors are a diverse group of aggressive cancers originating from mesenchymal cells in connective tissues such as bone, muscle, cartilage, and fat. These tumors often invade surrounding tissues and metastasize to distant organs, posing significant treatment challenges. Among them, malignant mesenchymal tumors located in the distal femur are particularly rare, with limited reports detailing effective surgical and functional reconstruction strategies following wide resection.
View Article and Find Full Text PDFProspective Head-to-Head Comparison of F-PSMA PET/CT and F-NaF PET/CT for Assessing Bone Metastases in 160 Patients with Newly Diagnosed High-Risk Prostate Cancer.
J Nucl Med
January 2025
Department of Nuclear Medicine, Aalborg University Hospital, Aalborg, Denmark.
Prostate-specific membrane antigen (PSMA) PET/CT is increasingly used for primary staging in prostate cancer (PC), mainly because of its improved accuracy in detecting lymph node metastases compared with conventional imaging. However, the diagnostic benefit of PSMA PET/CT for detecting bone metastases is less well established. This study compares the diagnostic accuracy of F-PSMA PET/CT and F-NaF PET/CT for detecting bone metastases in patients newly diagnosed with PC.
View Article and Find Full Text PDFSevere hypophosphataemia following denosumab administration successfully managed using a calcimimetic agent.
BMJ Case Rep
January 2025
Pediatrics, Shiga University of Medical Science, Otsu, Shiga, Japan.
Denosumab, an anti-RANKL antibody, induces bone metabolism to a low-turnover bone status by arresting osteoclast activity. Frequent adverse events include infusion reactions, fever and hypocalcaemia but not hypophosphataemia. We report a case of severe hypophosphataemia associated with secondary hyperparathyroidism following denosumab administration in a young boy with recurrent osteosarcoma who was successfully treated with evocalcet.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!